Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the ethical concerns and implications of a partnership between the National Prostate Cancer Coalition and Viadur, including the perceived endorsement of a specific drug.

This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This article discusses whether testosterone's metabolism to 5α-dihydrotestosterone is necessary for androgenic effects in the skin but reports no new experimental results.

This study found that the petroleum ether extract of Citrullus colocynthis fruit and an isolated steroidal compound may reduce prostatic hyperplasia in rats induced by testosterone, suggesting potential use in managing androgen-dependent conditions.

A new compound was made that might help treat diseases related to male hormones.

This case report highlights the growing trend of adolescents using Finasteride off-label for early hair loss, driven by online misinformation and psychological distress, despite potential side effects and hormonal concerns.

This analysis concluded that finasteride effectively reduces prostate size and urinary symptoms in benign prostatic hyperplasia, offering a favorable safety profile and versatility as a treatment option.

This review highlights that Serenoa repens exhibits anti-androgenic and anti-inflammatory activities, potentially alleviating benign prostate hyperplasia symptoms, with phytosterols and fatty acids as key active constituents, while suggesting more research into additional medicinal uses and phytochemicals is needed.

This article presents a therapeutic perspective on Proscar and Propecia for treating prostate conditions but reports no new research findings.

This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

This review summarizes the latest updates on using antiandrogens as potential prophylactic and therapeutic options for COVID-19, highlighting that androgen-mediated regulation of factors like TMPRSS2 and ACE2 is involved in SARS-CoV-2 infection, suggesting a strategy to block viral entry into cells.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This review discusses the molecular mechanisms of masculinization involving androgen signaling and their roles in male embryonic development and conditions like hypospadias and prostate cancer, and reports no clinical results.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

This review discusses the role of steroid 5 alpha reductase 2 in converting testosterone to DHT and its association with conditions like benign prostatic hyperplasia and prostate cancer; it reports no new results.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

This study discusses the role of 5α-reductase inhibitors in managing lower urinary tract symptoms caused by benign prostatic hyperplasia and suggests their potential use in other conditions like prostate cancer chemoprevention and androgenetic alopecia treatment, emphasizing appropriate dosing to reduce surgical complications.

This review summarizes key characteristics of men's health issues such as erectile dysfunction and prostate cancer, along with specific nursing considerations, and reports no new research results.

A bladder rupture from prostate treatment was healed with catheterization and antibiotics.

Finasteride effectively treats hair loss and prostate issues by blocking a specific enzyme.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This study concluded that finasteride may safely reduce prostate size and improve urinary symptoms for at least six years in men with benign prostatic hyperplasia, though further improvements beyond six months are unlikely.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.